Guardant360

DIAGNOSTIC_TEST4 trials

Sponsors

MedSIR, University Health Network, Toronto, Guardant Health, Inc.

Conditions

Breast CancerColorectal CancerLung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Unknown Phase

Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)

CompletedNCT03248089

MedSIRLung Cancer

Start: 2016-07-31End: 2019-01-31Updated: 2019-01-09

Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study

CompletedNCT03576937

University Health Network, TorontoNon-small Cell Lung Cancer

Start: 2019-02-12End: 2023-04-30Updated: 2023-05-15

Noninvasive vs. Invasive Lung Evaluation

CompletedNCT03615443

Guardant Health, Inc.Non-Small Cell Lung Cancer

Start: 2016-02-12End: 2020-11-23Updated: 2021-05-03

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

RecruitingNCT05935384

Guardant Health, Inc.Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer

Start: 2023-10-25End: 2030-12-30Target: 470Updated: 2026-09-11

Related Papers

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Therapeutic Advances in Medical Oncology2022-01-0147 citations

Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Journal of Clinical Oncology2021-05-201 citations

Demonstrating the value of liquid biopsy for lung cancer in a public health care system.

Journal of Clinical Oncology2020-05-204 citations

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Cancers2019-09-1768 citations

Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.

Journal of Clinical Oncology2019-05-201 citations